Hadźiev S, Kavaklieva-Dimitrova J, Mandulova P, Madźarova S, Spassova M
Neoplasma. 1980;27(1):83-94.
243 lung cancer patients treated with routine therapy (surgery 54, radiotherapy 46 and chemotherapy 143) in Plovdiv's District Oncologic Dispensary (PDOD) were submitted to an additional therapy with BCG or with its soluble fraction F70. The survival rate of these patients was compared with the survival rate of 305 lung cancer patients following routine therapy alone (surgery 78, radiotherapy 113 and chemotherapy 114). The two groups were not randomized. Between patients treated and non-treated with BCG(F70) a significant increase of the survival rate was found for patients submitted to BCG(F70) treatment after surgery or radiotherapy in the 2nd and 3rd year survival period and for patients submitted to BCG(F70) treatment after chemotherapy -- in the 1st year survival period of patients with limited disease only. The effect of the additional BCG(F70) treatment was less dependent on the preceding routine therapy than upon the clinical stage of the disease at the moment of BCG(F70) treatment beginning. More salient results were observed in patients with undifferentiated histological forms.
普罗夫迪夫地区肿瘤防治所（PDOD）的243例接受常规治疗（手术54例、放疗46例、化疗143例）的肺癌患者接受了卡介苗或其可溶性组分F70的辅助治疗。将这些患者的生存率与305例仅接受常规治疗（手术78例、放疗113例、化疗114例）的肺癌患者的生存率进行比较。两组未进行随机分组。在接受和未接受卡介苗（F70）治疗的患者中，发现接受卡介苗（F70）治疗的患者在术后或放疗后的第2年和第3年生存期以及接受化疗后接受卡介苗（F70）治疗的患者（仅疾病局限患者的第1年生存期）的生存率显著提高。辅助卡介苗（F70）治疗的效果与其之前的常规治疗的相关性小于与开始卡介苗（F70）治疗时疾病临床分期的相关性。在组织学类型为未分化型的患者中观察到更显著的结果。
